Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemia
Open Access
- 20 October 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (5), 1183-1195
- https://doi.org/10.1111/j.1476-5381.2009.00389.x
Abstract
Background and purpose: γ‐Secretase inhibitors (GSIs) block NOTCH receptor cleavage and pathway activation and have been under clinical evaluation for the treatment of malignancies such as T‐cell acute lymphoblastic leukaemia (T‐ALL). The ability of GSIs to decrease T‐ALL cell viability in vitro is a slow process requiring >8 days, however, such treatment durations are not well tolerated in vivo. Here we study GSI's effect on tumour and normal cellular processes to optimize dosing regimens for anti‐tumour efficacy. Experimental approach: Inhibition of the Notch pathway in mouse intestinal epithelium was used to evaluate the effect of GSIs and guide the design of dosing regimens for xenograft models. Serum Aβ40 and Notch target gene modulation in tumours were used to evaluate the degree and duration of target inhibition. Pharmacokinetic and pharmacodynamic correlations with biochemical, immunohistochemical and profiling data were used to demonstrate GSI mechanism of action in xenograft tumours. Key results: Three days of >70% Notch pathway inhibition was sufficient to provide an anti‐tumour effect and was well tolerated. GSI‐induced conversion of mouse epithelial cells to a secretory lineage was time‐ and dose‐dependent. Anti‐tumour efficacy was associated with cell cycle arrest and apoptosis that was in part due to Notch‐dependent regulation of mitochondrial homeostasis. Conclusions and implications: Intermittent but potent inhibition of Notch signalling is sufficient for anti‐tumour efficacy in these T‐ALL models. These findings provide support for the use of GSI in Notch‐dependent malignancies and that clinical benefits may be derived from transient but potent inhibition of Notch.Keywords
This publication has 53 references indexed in Scilit:
- Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal AdenocarcinomaGastroenterology, 2009
- ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenesProceedings of the National Academy of Sciences of the United States of America, 2009
- γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemiaNature Medicine, 2008
- Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2EMBO Reports, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitorsThe Journal of Experimental Medicine, 2007
- NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growthProceedings of the National Academy of Sciences of the United States of America, 2006
- c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphomaGenes & Development, 2006
- Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesisThe Journal of cell biology, 2004
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004